Bibliography
- Liu AM, Xu MZ, Chen J, Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 2010;14:855-68
- Benhamouche S, Curto M, Saotome I, Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010;24:1718-30
- Thomas MB, Morris JS, Chadha R, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50
- Zhou D, Conrad C, Xia F, Mst1 and Mst2 maintain hepatocytequiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16:425-38
- Lu L, Li Y, Kim SM, Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010;107:1437-42
- Guo C, Tommasi S, Liu L, RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007;17:700-5
- Lee KP, Lee JH, Kim TS, The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:8248-53
- St John MA, Tao W, Fei X, Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999;21:182-6
- McPherson JP, Tamblyn L, Elia A, Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. Embo J 2004;23:3677-88
- Cho WJ, Shin JM, Kim JS, miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009;28:521-7
- Lee KH, Goan YG, Hsiao M, MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 2009;315:2529-38
- Zhao B, Li L, Tumaneng K, A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFbeta-TRCP. Genes Dev 2010;24:72-85
- Wang P, Bai Y, Song B, PP1A-mediated dephosphorylation positively regulates YAP2 activity. PLoS One 2011;6:e24288
- Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2011; published online 29 August 2011; doi:10.1038/onc.2011.363
- Tian W, Yu J, Tomchick DR, Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA 2010;107:7293-8
- Li Z, Zhao B, Wang P, Structural insights into the YAP and. TEAD complex. Genes Dev 2010;24:235-40
- Zhao B, Li L, Lu Q, Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011;25:51-63
- Chan SW, Lim CJ, Chong YF, Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011;286:7018-26
- Paramasivam M, Sarkeshik A, Yates JR III, Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011;22:3725-33
- Oka T, Remue E, Meerschaert K, Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010;432:461-72
- Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012;31:128-34
- Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010;394:623-7
- Kowalik MA, Saliba C, Pibiri M, Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011;53:2086-96